{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 2 Flash Glucose Monitoring System",
        "FreeStyle Libre 3 Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care Inc.",
    "510(k) Number": "K222447",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210943",
        "K213996",
        "K212132"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "NBW"
    ],
    "Summary Letter Date": "August 12, 2022",
    "Summary Letter Received Date": "August 15, 2022",
    "Submission Date": "March 1, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 2 Reader",
        "FreeStyle Libre 2 App",
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 App",
        "Libre Data Sharing API"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Electrochemical sensor"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Factory calibration",
        "Digital wireless communication"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "App",
        "Reader",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott FreeStyle Libre 2 and Libre 3 integrated continuous glucose monitoring systems with modified sensor tail for diabetes management.",
    "Indications for Use Summary": "Continuous glucose monitoring systems with alarms capability indicated for management of diabetes in persons age 2 and older; intended to replace blood glucose testing for diabetes treatment decisions and to communicate with digitally connected devices including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}